1 – 15 of 20
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
- 2021
-
Mark
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Principles of Care for Acquired Hemophilia
(
- Contribution to journal › Article
-
Mark
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B : a PedNet study
(
- Contribution to journal › Article
- 2020
-
Mark
WFH Guidelines for the Management of Hemophilia, 3rd edition
(
- Contribution to journal › Article
- 2019
-
Mark
Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
(
- Contribution to journal › Letter
-
Mark
Inhibitors in haemophilia A and B : Management of bleeds, inhibitor eradication, and strategies for difficult-to-treat patients
(
- Contribution to journal › Scientific review
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
(
- Contribution to journal › Scientific review
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article
- 2018
-
Mark
Practical aspects of extended half-life products for the treatment of haemophilia
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
(
- Contribution to journal › Article
-
Mark
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors
(
- Contribution to journal › Article
- 2016
-
Mark
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels.
(
- Contribution to journal › Scientific review
-
Mark
Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors
(
- Contribution to journal › Article
- 2015
-
Mark
Switching treatments in haemophilia: is there a risk of inhibitor development?
(
- Contribution to journal › Scientific review